Susquehanna International Group, LLP Anavex Life Sciences Corp. Put Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 14, 2025	BUY	$5.11 - $12.56 $456,323 - $1.12 Million	89,300 Added 47.35%	277,900 $2.98 Million
Q3 2024 Nov 14, 2024	BUY	$4.11 - $7.04 $275,370 - $471,680	67,000 Added 55.1%	188,600 $1.07 Million
Q2 2024 Aug 15, 2024	SELL	$3.39 - $5.02 $471,888 - $698,783	-139,200 Reduced 53.37%	121,600 $513,000
Q1 2024 May 07, 2024	SELL	$4.55 - $6.75 $1.76 Million - $2.62 Million	-387,500 Reduced 59.77%	260,800 $1.33 Million
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $807,912 - $1.59 Million	160,300 Added 32.85%	648,300 $6.04 Million
Q3 2023 Nov 14, 2023	BUY	$6.55 - $9.37 $294,750 - $421,649	45,000 Added 10.16%	488,000 $3.2 Million
Q2 2023 Aug 11, 2023	SELL	$7.66 - $9.5 $430,492 - $533,900	-56,200 Reduced 11.26%	443,000 $3.6 Million
Q1 2023 May 16, 2023	SELL	$8.32 - $11.75 $1.56 Million - $2.2 Million	-187,000 Reduced 27.25%	499,200 $4.28 Million
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $590,580 - $1.11 Million	77,200 Added 12.68%	686,200 $6.35 Million
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $767,180 - $1.11 Million	86,200 Added 16.49%	609,000 $6.29 Million

182

28.9M

749K

825K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $664M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.